by Manon FRACHON | 12 May Tue | Without category
Jeito[1] reaffirms its commitment by participating in the IPO, following its significant investment in Odyssey’s recent oversubscribed $213 million series D financing round This renewed support underscores the company’s innovation potential for patients with...
by Manon FRACHON | 14 Apr Tue | English
Proceeds from the financing will support the advancement of three first- and best-in-class ADC[1] programs through upcoming key clinical milestones While oncology continues to face substantial and largely unmet needs, Jeito will leverage its expertise to accelerate...
by Manon FRACHON | 11 Mar Wed | Without category
Samit Hirawat, M.D., brings over 25 years of senior leadership and clinical development experience at top-tier international pharmaceutical groups, including Novartis and Bristol Myers Squibb, further enhancing Jeito’s strategic capabilities. His expertise will...
by Manon FRACHON | 24 Feb Tue | Without category
Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program ALV‑100 designed to deliver potent, durable weight loss and long‑term maintenance with improved tolerability. The financing will also support Investigational New Drug...
by Manon FRACHON | 15 Oct Wed | English
Paris, France, October 15th, 2025 – Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to biopharma, today announced the promotion of Ksenija Pavletic to General Partner, reinforcing the firm’s senior leadership team as it continues to...
Recent Comments